Posted by Michael Wonder on 06 Sep 2022
Italian Medicines Agency approves reimbursed access to Bylvay (odevixibat) for patients with all PFIC types
6 September 2022 - Positive Agenzia Italiana del Farmaco (AIFA) decision provides reimbursed access to the first medicine available for the treatment of all types of progressive familial intrahepatic cholestasis, a rare and devastating disorder that affects young children and causes progressive, life-threatening liver disease.
Albireo Pharma today announced that the Italian Medicines Agency, also known as Agenzia Italiana del Farmaco (AIFA), has enabled reimbursed access to Bylvay (odevixibat) for the treatment of all types of progressive familial intrahepatic cholestasis patients in Italy.
